Novel Gastrointestinal Therapies

Gastrointestinal (GI) disorders will affect more than 250 million people in the seven largest pharmaceutical markets by 2012. Reflecting its importance in the pharmaceutical industry, the market to treat GI disorders is valued at more than US$20 billion. Early detection of GI malignancies, when they are limited to the mucosa and have a low risk of metastasis, is the rationale for screening patients for early gastric cancer and colorectal cancer. Such lesions are potentially curable with endoscopic therapy. Colonoscopy remains the standard for detection of abnormalities in the colon. However, research has shown that a significant number of polyps and cancers may be missed during colonoscopy. To address this gap, new methods and devices, such as high-resolution, magnification and light autofluorescence endoscopy and chromoendoscopy, among others, are being developed to improve the detection and treatment of colorectal cancer and other gastrointestinal issues.

This event will focus on exploring new technologies, both available and under development, that will dramatically improve the treatment of gastrointestinal diseases.

The registration fee for the event is US$40 per person.

Please make checks payable to Squire, Sanders & Dempsey L.L.P. and send to:

Squire, Sanders & Dempsey L.L.P.

Attn: Angela Isola

One Maritime Plaza

Suite 300

San Francisco, CA 94111-3492

For more information, contact Angela Isola at +1.415.393.9864.